This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Alzheimer's Disease & Dementia Conference" (Dementia 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at dementia@magnusconference.com or call + 1 (702) 988 2320.
Alzheimer's disease is the most common suffering from dementia disease and is a gradual, permanent, incurable neurodegenerative illness. It usually begins after the age of 60 and lasts for 8 to 12 years. Cognitive degradation, loss of functional independence, behavioral changes, and an increase in the need for care are all symptoms of this disease's slow and steady progression. The burden of neocortical neurofibrillary tangles was found to have a pathological correlation of cognitive impairment in clinicopathological studies. The most prevalent symptom of Alzheimer's disease is a persistent impairment in episodic memory.
Important Alert:
X
Title : Early clinical development of modified P8 for the treatment of alzheimer’s disease
Nazneen N Dewji, Cenna Biosciences Inc, United States
Title : Who cares for the carers
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Efficacy of transcranial photobiomodulation in mild cognitive impairment and early alzheimer’s Disease: A randomized controlled study
Hyelim Chun, St.Peter’s General Hospital, Korea, Republic of